21 analysts have recently updated their ratings on Humana (NYSE:HUM), showing a diverse range of perspectives from bullish to bearish. The average 12-month price target is now $428.95, a 15.62% decline from the previous average, with adjustments made by analysts from firms including Wells Fargo, Goldman Sachs, and Barclays. Humana's financial performance indicates a revenue growth rate of 17.93% as of December 31, 2023, but challenges in net margin and debt management are noted. The company's focus on government-sponsored programs and healthcare services positions it uniquely in the health insurance sector.